Veto cells

Veto cells are white blood cells that have a selective immunomodulation properties.[1][2] Veto cells were first described in 1979 as cells that “can prevent generation of cytotoxic lymphocytes by normal spleen cells against self-antigens”.[3] Hence, veto cells delete T cells that recognize the veto cells (the responding T cells are “vetoed” and thus removed from the system).[4][5][6]

Proposed role in homeostasis

The establishment and maintenance of self-tolerance is an essential property of an immune system designed to eliminate foreign substances. Avoiding self-reactivity in the T cell compartment is maintained by: clonal deletion in the thymus and suppressive cells that eliminate or induce tolerance on autoreactive lymphocytes that escaped selection. Veto activity is thought to be a form of antigen-specific suppression that maintains continuous self-tolerance. Cells with veto activity induce a state of tolerance in T cell precursors with specificity for antigen determinants expressed on the surface of the veto-active cell. This means that T-cells with a T-cell receptor specific to antigens presented on the veto cell, bind to the veto cell, and are in-turn tolerized or eliminated. Hence veto activity is selective but is not T-cell receptor mediated. Both clonal anergy and clonal deletion have been shown to operate in vetoed T cells. The veto cell need only carry the self-MHC determinant or self-MHC determinant plus antigen.[5] Veto-induced tolerance can be established in vitro and in vivo for both MHC class I and II as well as minor histocompatibility antigens.[6]

Types

Veto activity is a functional hallmark of a cell, it is not a specific phenotype. This means that different types of white blood cells, including non-cytotoxic cells, are capable of acting as veto cells. To name some of these cell types; CD34 cells,[7] CD33 cells,[8] CD8 T cells,[6] Immature dendritic cells [9] and NK cells[10][11] among others.

Mature activated cytotoxic CD8+ T cells are the most potent veto cells, this is perhaps related to their distinct function as killer cells which is not related to their veto activity. Subtypes of CD8+ T cells such as Central memory T-cell are also excellent veto cells.[12]

Mechanisms of action

Different veto cells possess different elimination mechanisms and tolerance induction mechanisms. Both CD34 and CD33 cells function via the TNFα pathway.[13]

Mature activated cytotoxic CD8+ T cells vetoeing involves ligation of MHCI on the target cell by CD8 on the veto cell and killing can then be mediated via either the Fas/FASL pathway [14] or the Perforin mediated apoptosis pathways.[15]

BM-derived immature dendritic cells vetoeing mechanism against CD8 T cells was found to be an MHC-dependent binding followed by mediated killing that involves TLR7, and TREM1.[9]

Veto cells in allogeneic/haploidentical transplantation

Because veto cells can only suppress T-cell progenitors that are directed against antigens on the veto cells themselves, but not against third-party antigens, this specificity can be harnessed as an effective tool to create tolerance in transplantation. By isolating veto cells that express the MHC of the donor it is possible to eliminate/tolerize only T-cell precursors that recognize the donor. These are the same T-cells that mediate graft rejection. This means that the addition of donor-veto cells to the donor graft can act as a specific immunosuppressant, only eliminating the cells that mediate graft rejection, but the rest of the T cellclone s (those that do not recognize the donor MHC/antigen) can provide immunity to the host normally.

CD34+ cells were serendipitously found to have veto activity when researchers were trying to solve the problem of Graft rejection of T-cell depleted Hematopoietic stem cell transplantation in leukemia patients. After this discovery a new type of transplantation - megadose transplantation - using a high number of CD34 cells was established.[7][16] The large number of veto cells helped overcome the graft rejection that was mediated by the host CD8 T-cell precursors.[17]

An alternative to isolation and transplantation of large amounts of CD34+ cells is to add other types of veto cells and transplant them along with the graft. This method is especially handy when using conditioning regimens that are not as toxic and immune depleting as traditional methods. These are called reduced intensity or non-myeloablative conditioning regimens and since these protocols do not completely abolish the immune system of the host, Graft rejection is the main problem. Addition of donor-veto cells to the graft can provide one solution to this problem.

Veto cell administration can also be used for tolerance induction to allogeneic/haploidentical solid organ grafts. This has been tested successfully in kidney transplant model in unrelated outbred rhesus monkeys.[18] and skin transplants in mice.[12] Other experiments have been unsuccessful.[19]

Anti-3rd party veto cells

Anti-3rd party veto cells were developed to address the need for large numbers of donor veto cells to infuse along with the graft, as a tool for the induction of donor-tolerance.[20] These cells are produced from naive donor CD8+ cells because CD8+ cells have the best veto activity. By expanding naïve CD8 T cells against 3rd-party stimulators under cytokine deprivation, clones that are reactive against the host are eliminated due to lack of nutrients and signaling. The expression of a central memory T cell (Tcm) phenotype helps these host non-reactive veto cells reach the lymph nodes where they eradicate anti-donor T cell precursors. Transfer of these Anti-3rd party Tcm with megadose TCD HSCT in preclinical models was successful at preventing graft rejection without GVHD under reduced intensity conditioning.[12][20]

Therapy

Anti-3rd party veto cells can also be manipulated to become genetically engineered T cell. In this case, veto cells from an allogeneic/haploidentical donor can exert some therapeutic function while also avoiding rejection through their veto activity. One study shows that this could be an effective solution for the production of off-the-shelf CAR T cells that will not be rejected or cause GvHD.[21]

Anti-3rd party veto cells have also been shown to have Graft-versus-tumor effect[22]

gollark: The internal M.2 slot functionality *is* pretty nice, though, I must say.
gollark: Having options is probably a good thing, but Librem seems more focused on a full FOSSy ecosystem for communication and whatnot rather than just hardware like PinePhone.
gollark: Is there a plan for a transparent back cover? It might be cool to be able to see the insides.
gollark: The mobile reddit site seems to crash and break randomly for me. I have got to find an alternative some time.
gollark: New reddit is HERESY.

References
  1. Ophir, Eran; Reisner, Yair (2012-05-02). "The use of donor-derived veto cells in hematopoietic stem cell transplantation". Frontiers in Immunology. US. 3: 93. doi:10.3389/fimmu.2012.00093. PMC 3341989. PMID 22566971.
  2. Reich-Zeliger, S.; Zhao, Y.; Krauthgamer, R.; Bachar-Lustig, E.; Reisner, Y. (2000-10-01). "Anti-Third Party CD8+ CTLs as Potent Veto Cells: Coexpression of CD8 and FasL Is a Prerequisite". Immunity. 13 (4): 507–515. doi:10.1016/S1074-7613(00)00050-9. PMID 11070169.
  3. Miller, RG; Derry, H (April 1979). "A cell population in nu/nu spleen can prevent generation of cytotoxic lymphocytes by normal spleen cells against self-antigens of the nu/nu spleen". Journal of Immunology. 122 (4): 1502–9. PMID 312845.
  4. Miller, RG (9 October 1980). "An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it". Nature. 287 (5782): 544–6. Bibcode:1980Natur.287..544M. doi:10.1038/287544a0. PMID 6448351.
  5. Miller, RG; Muraoka, S; Claesson, MH; Reimann, J; Benveniste, P (1988). "The veto phenomenon in T-cell regulation". Annals of the New York Academy of Sciences. 532 (1): 170–6. Bibcode:1988NYASA.532..170M. doi:10.1111/j.1749-6632.1988.tb36336.x. PMID 2972242.
  6. Tscherning, T; Claësson, MH (1993). "Veto suppression: the peripheral way of T cell tolerization". Experimental and Clinical Immunogenetics. 10 (4): 179–88. PMID 7907886.
  7. Rachamim, N; Gan, J; Segall, H; Krauthgamer, R; Marcus, H; Berrebi, A; Martelli, M; Reisner, Y (27 May 1998). "Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture". Transplantation. 65 (10): 1386–93. doi:10.1097/00007890-199805270-00017. PMID 9625023.
  8. Gur, H; Krauthgamer, R; Berrebi, A; Klein, T; Nagler, A; Tabilio, A; Martelli, MF; Reisner, Y (1 June 2002). "Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells". Blood. 99 (11): 4174–81. doi:10.1182/blood.v99.11.4174. PMID 12010823.
  9. Zangi, L; Klionsky, YZ; Yarimi, L; Bachar-Lustig, E; Eidelstein, Y; Shezen, E; Hagin, D; Ito, Y; Takai, T; Reich-Zeliger, S; Lask, A; Milstein, O; Jung, S; Shinder, V; Reisner, Y (23 August 2012). "Deletion of cognate CD8 T cells by immature dendritic cells: a novel role for perforin, granzyme A, TREM-1, and TLR7". Blood. 120 (8): 1647–57. doi:10.1182/blood-2012-02-410803. PMID 22776817.
  10. Chrobak, P; Gress, RE (15 March 2001). "Veto activity of activated bone marrow does not require perforin and Fas ligand". Cellular Immunology. 208 (2): 80–7. doi:10.1006/cimm.2001.1771. PMID 11333140.
  11. Reich-Zeliger, S; Bachar-Lustig, E; Gan, J; Reisner, Y (1 December 2004). "Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells". Journal of Immunology. 173 (11): 6654–9. doi:10.4049/jimmunol.173.11.6654. PMID 15557156.
  12. Ophir, E; Or-Geva, N; Gurevich, I; Tal, O; Eidelstein, Y; Shezen, E; Margalit, R; Lask, A; Shakhar, G; Hagin, D; Bachar-Lustig, E; Reich-Zeliger, S; Beilhack, A; Negrin, R; Reisner, Y (14 February 2013). "Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells". Blood. 121 (7): 1220–8. doi:10.1182/blood-2012-07-441493. PMC 4467899. PMID 23223359.
  13. Gur, H; Krauthgamer, R; Bachar-Lustig, E; Katchman, H; Arbel-Goren, R; Berrebi, A; Klein, T; Nagler, A; Tabilio, A; Martelli, MF; Reisner, Y (15 March 2005). "Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha". Blood. 105 (6): 2585–93. doi:10.1182/blood-2002-11-3463. PMID 15471953.
  14. Reich-Zeliger, S; Zhao, Y; Krauthgamer, R; Bachar-Lustig, E; Reisner, Y (October 2000). "Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite". Immunity. 13 (4): 507–15. doi:10.1016/s1074-7613(00)00050-9. PMID 11070169.
  15. Milstein, O; Hagin, D; Lask, A; Reich-Zeliger, S; Shezen, E; Ophir, E; Eidelstein, Y; Afik, R; Antebi, YE; Dustin, ML; Reisner, Y (20 January 2011). "CTLs respond with activation and granule secretion when serving as targets for T-cell recognition". Blood. 117 (3): 1042–52. doi:10.1182/blood-2010-05-283770. PMC 3035066. PMID 21045195.
  16. Or-Geva, N; Reisner, Y (March 2016). "The evolution of T-cell depletion in haploidentical stem-cell transplantation". British Journal of Haematology. 172 (5): 667–84. doi:10.1111/bjh.13868. PMID 26684279.
  17. Or-Geva, N; Reisner, Y (August 2014). "Megadose stem cell administration as a route to mixed chimerism". Current Opinion in Organ Transplantation. 19 (4): 334–41. doi:10.1097/MOT.0000000000000095. PMID 24905022.
  18. Thomas, JM; Verbanac, KM; Carver, FM; Kasten-Jolly, J; Haisch, CE; Gross, U; Smith, JP (April 1994). "Veto cells in transplantation tolerance". Clinical Transplantation. 8 (2 Pt 2): 195–203. PMID 8019036.
  19. Naar, JD; Fisher, RA; Saggi, BH; Wakely PE, Jr; Tawes, JW; Posner, MP (1 July 1998). "Flow cytometric analysis of chimerism in the rat tolerant to a renal allograft". The Journal of Surgical Research. 77 (2): 179–86. doi:10.1006/jsre.1998.5373. PMID 9733606.
  20. Or-Geva, N; Reisner, Y (June 2015). "The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT". Bone Marrow Transplantation. 50 Suppl 2: S14–20. doi:10.1038/bmt.2015.89. PMID 26039201.
  21. Or-Geva, N; Gidron-Budovsky, R; Radomir, L; Edelstein, Y; Singh, AK; Sidlik-Muskatel, R; Ophir, E; Bachar-Lustig, E; Reisner, Y (April 2018). "Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells". Leukemia. 32 (4): 1039–1041. doi:10.1038/leu.2017.332. PMID 29151584.
  22. Lask, A; Ophir, E; Or-Geva, N; Cohen-Fredarow, A; Afik, R; Eidelstein, Y; Reich-Zeliger, S; Nathansohn, B; Edinger, M; Negrin, RS; Hagin, D; Reisner, Y (11 April 2013). "A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells". Blood. 121 (15): 3033–40. doi:10.1182/blood-2012-06-432443. PMC 4467889. PMID 23446736.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.